JP6856648B2 - Ｃｘｃｒ４受容体アンタゴニスト - Google Patents
Ｃｘｃｒ４受容体アンタゴニスト Download PDFInfo
- Publication number
- JP6856648B2 JP6856648B2 JP2018531058A JP2018531058A JP6856648B2 JP 6856648 B2 JP6856648 B2 JP 6856648B2 JP 2018531058 A JP2018531058 A JP 2018531058A JP 2018531058 A JP2018531058 A JP 2018531058A JP 6856648 B2 JP6856648 B2 JP 6856648B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- alkyl
- pyrimidin
- imidazole
- tetrahydroquinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- IKNRJDJMXRYEOK-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1c1nc(OC)cc2nc(C=O)c[n]12)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1c1nc(OC)cc2nc(C=O)c[n]12)=O IKNRJDJMXRYEOK-UHFFFAOYSA-N 0.000 description 1
- HOMUSTSFVNRTAX-UHFFFAOYSA-N CCOC(c1c[n]2c(O)nccc2n1)=O Chemical compound CCOC(c1c[n]2c(O)nccc2n1)=O HOMUSTSFVNRTAX-UHFFFAOYSA-N 0.000 description 1
- RKUCPMGCBOAYKR-IBGZPJMESA-N CN(Cc1c[n]2c(N3CCN(C)CC3)nccc2n1)[C@@H]1c2ncccc2CCC1 Chemical compound CN(Cc1c[n]2c(N3CCN(C)CC3)nccc2n1)[C@@H]1c2ncccc2CCC1 RKUCPMGCBOAYKR-IBGZPJMESA-N 0.000 description 1
- UENRYYSJOAZKNV-FQEVSTJZSA-N CN(Cc1c[n]2c(N3CCN(CCO)CC3)nccc2n1)[C@@H]1c2ncccc2CCC1 Chemical compound CN(Cc1c[n]2c(N3CCN(CCO)CC3)nccc2n1)[C@@H]1c2ncccc2CCC1 UENRYYSJOAZKNV-FQEVSTJZSA-N 0.000 description 1
- COKHEGJHRXFRDY-UHFFFAOYSA-N CSc1nccc2nc(C(Cl)Cl)c[n]12 Chemical compound CSc1nccc2nc(C(Cl)Cl)c[n]12 COKHEGJHRXFRDY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267649P | 2015-12-15 | 2015-12-15 | |
| US62/267,649 | 2015-12-15 | ||
| PCT/US2016/066575 WO2017106291A1 (en) | 2015-12-15 | 2016-12-14 | Cxcr4 receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019502680A JP2019502680A (ja) | 2019-01-31 |
| JP2019502680A5 JP2019502680A5 (2) | 2020-01-23 |
| JP6856648B2 true JP6856648B2 (ja) | 2021-04-07 |
Family
ID=57755467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531058A Active JP6856648B2 (ja) | 2015-12-15 | 2016-12-14 | Ｃｘｃｒ４受容体アンタゴニスト |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10450318B2 (2) |
| EP (1) | EP3390406A1 (2) |
| JP (1) | JP6856648B2 (2) |
| KR (1) | KR102738306B1 (2) |
| CN (1) | CN108602829A (2) |
| WO (1) | WO2017106291A1 (2) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018225556A1 (en) | 2017-02-21 | 2019-10-03 | Emory University | Chemokine CXCR4 receptor modulators and uses related thereto |
| CN109553604B (zh) * | 2017-09-25 | 2021-08-27 | 盛世泰科生物医药技术(苏州)有限公司 | 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用 |
| US11649235B2 (en) | 2018-03-19 | 2023-05-16 | Emory University | Pan-tropic entry inhibitors |
| CN115403510B (zh) * | 2022-08-11 | 2023-04-25 | 南方医科大学 | 一种pd-l1/cxcl12双靶点抑制剂、制备方法和用途 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0127547D0 (en) * | 2001-11-16 | 2002-01-09 | Astrazeneca Ab | Chemical compounds |
| UA80571C2 (en) | 2002-11-22 | 2007-10-10 | Lilly Co Eli | Quinolinyl-pyrrolopyrazoles |
| MX2007002679A (es) * | 2004-09-02 | 2007-05-16 | Smithkline Beecham Corp | Compuestos quimicos. |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| JP2008524255A (ja) * | 2004-12-17 | 2008-07-10 | スミスクライン ビーチャム コーポレーション | 化学物質 |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| PT1910370E (pt) | 2005-07-22 | 2015-06-30 | Lilly Co Eli | Um pirrolo[1,2-b]pirazole mono-hidratado substituído com piridina e quinolina como inibidor do tgf-beta |
| US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| PE20070946A1 (es) | 2006-01-25 | 2007-10-16 | Smithkline Beecham Corp | COMPUESTOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO MODULADORES DEL RECEPTOR DE QUIMIOQUINA (CXCR4) |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| CN103372215B (zh) | 2008-01-03 | 2016-03-09 | 艾克斯-马赛大学 | 抗hiv治疗期间使用的组合物和方法 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| US8080568B1 (en) | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| NO2694640T3 (2) | 2011-04-15 | 2018-03-17 | ||
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
-
2016
- 2016-12-14 JP JP2018531058A patent/JP6856648B2/ja active Active
- 2016-12-14 EP EP16823109.0A patent/EP3390406A1/en not_active Withdrawn
- 2016-12-14 CN CN201680081803.1A patent/CN108602829A/zh active Pending
- 2016-12-14 KR KR1020187019798A patent/KR102738306B1/ko active Active
- 2016-12-14 US US15/776,936 patent/US10450318B2/en active Active
- 2016-12-14 WO PCT/US2016/066575 patent/WO2017106291A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US10450318B2 (en) | 2019-10-22 |
| CN108602829A (zh) | 2018-09-28 |
| EP3390406A1 (en) | 2018-10-24 |
| WO2017106291A1 (en) | 2017-06-22 |
| JP2019502680A (ja) | 2019-01-31 |
| US20180327409A1 (en) | 2018-11-15 |
| KR102738306B1 (ko) | 2024-12-03 |
| KR20180094036A (ko) | 2018-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2961740C (en) | N-pyridinyl acetamide derivatives as wnt signalling pathway inhibitors | |
| JP6639497B2 (ja) | ブロモドメインインヒビターおよびその使用 | |
| JP7254821B2 (ja) | 抗がん剤としての環状ジヌクレオチド | |
| TWI866258B (zh) | 用於治療發炎性病症之新穎化合物及其醫藥組合物 | |
| US20200392161A1 (en) | Shp2 phosphatase inhibitors and methods of use thereof | |
| KR20250113487A (ko) | 화합물 | |
| WO2017117474A1 (en) | Bifunctional compounds for her3 degradation and methods of use | |
| JP2019516759A (ja) | がんの処置のためのピラゾロピリジン誘導体 | |
| AU2017290748A1 (en) | Pyrimidine-based antiproliferative agents | |
| WO2017117473A1 (en) | Bifunctional molescules for her3 degradation and methods of use | |
| JP2022511112A (ja) | Ａｌｋ５阻害剤としてのナフチリジンおよびキノリン誘導体 | |
| JP2017533248A (ja) | ブロモドメインのインヒビターとしての置換ピロロピリジン | |
| TW200908983A (en) | Heterocyclic compounds and uses thereof | |
| JP2021519308A (ja) | 転写活性化タンパク質のイミダゾピペラジン阻害剤 | |
| EP3256450B1 (en) | Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof | |
| TW201718546A (zh) | 適用作pim激酶抑制劑之雜環化合物 | |
| EP3237415A1 (en) | Tgf receptor antagonists | |
| JP6856648B2 (ja) | Ｃｘｃｒ４受容体アンタゴニスト | |
| JP2021513562A (ja) | 抗がん剤としての環状ジヌクレオチド | |
| WO2016198908A1 (en) | Ror nuclear receptor modulators | |
| JP2018528951A (ja) | ＴＧＦβ受容体アンタゴニスト | |
| JP2018525415A (ja) | Ｔｇｆベータ受容体アンタゴニスト | |
| US20130184273A1 (en) | Bicyclic pyrimidines | |
| JP2018526344A (ja) | Ｔｇｆベータ受容体アンタゴニスト | |
| CA3238595A1 (en) | 15-pgdh inhibitor and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191209 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191209 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201112 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201208 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201214 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210309 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210318 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6856648 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |